SynthesisFrontiers in endocrinology2026
Linking the triglyceride-glucose index to major adverse cardiocerebrovascular events in individuals with cardiovascular-kidney-metabolic syndrome: insights from an aggregate-data systematic review and dose-response meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidemiological research has indicated a potential association between the triglyceride-glucose (TyG) index and the risk of major adverse cardiocerebrovascular events (MACCE). Nevertheless, the precise nature and magnitude of this relationship remain to be fully elucidated. Objectives: This study aims to assess the dose-response relationship between the TyG index and MACCE among individuals with cardiovascular-kidney-metabolic (CKM) syndrome. Methods: A comprehensive literature search was conducted using the PubMed and Web of Science databases to identify relevant studies on the TyG-MACCE relationship up to 16 June 2026. Data were synthesized using both random- and fixed-effects models, and nonlinear dose-response meta-analyses were performed using restricted cubic spline models. Results: The analysis incorporated eight cohort studies, encompassing over two million participants and 179 thousand MACCE cases. The aggregated risk estimate for MACCE, comparing the highest to the lowest categories of TyG index exposure, was 1.20 (95% confidence interval [CI] Conclusions: This suggests that the TyG index may contribute to adverse MACCE in individuals with CKM syndrome. Further studies are needed to confirm causality and the predictive power of the TyG index. The research was prospectively registered in the Prospective Register for Systematic Reviews (registration number: CRD420261278535). Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261278535, identifier CRD420261278535.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.